|
|
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5446-5456.
Prepublished online as a Blood First Edition Paper on January 23, 2008; DOI 10.1182/blood-2007-06-093906.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLE
This is a new version, updated and corrected, as of December 8, 2008.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek1,
Bruce D. Cheson2,
Daniel Catovsky3,
Federico Caligaris-Cappio4,
Guillaume Dighiero5,
Hartmut Döhner6,
Peter Hillmen7,
Michael J. Keating8,
Emili Montserrat9,
Kanti R. Rai10, and
Thomas J. Kipps11
1 Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany;
2 Georgetown University Hospital, Lombardi Cancer Center, Washington, DC;
3 Institute of Cancer Research, London, United Kingdom;
4 Universita Vita-Salute Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Milano, Italy;
5 Institute Pasteur, Montevideo, Uruguay;
6 University of Ulm, Ulm, Germany;
7 St James's Institute of Oncology, Leeds, United Kingdom;
8 Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston;
9 Hospital Clinic, IDIBAPS, Barcelona, Spain;
10 Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; and
11 Rebecca and John Moores Cancer Center, University of California–San Diego, La Jolla
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute–sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?
- Curtis A. Hanson, Paul J. Kurtin, and Ahmet Dogan
Blood 2009 113: 6495-6496.
[Full Text]
[PDF]
-
Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL)
- Christopher S. Mulligan, Miriam E. Thomas, and Stephen P. Mulligan
Blood 2009 113: 6496-6497.
[Full Text]
[PDF]
-
Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al
- Peter Hillmen, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Doehner, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps, and Michael Hallek
Blood 2009 113: 6497-6498.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
L.-A. Sutton, E. Kostareli, A. Hadzidimitriou, N. Darzentas, A. Tsaftaris, A. Anagnostopoulos, R. Rosenquist, and K. Stamatopoulos
Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen
Blood,
November 12, 2009;
114(20):
4460 - 4468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Enzler, A. P. Kater, W. Zhang, G. F. Widhopf II, H.-Y. Chuang, J. Lee, E. Avery, C. M. Croce, M. Karin, and T. J. Kipps
Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression
Blood,
November 12, 2009;
114(20):
4469 - 4476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Visone, L. Z. Rassenti, A. Veronese, C. Taccioli, S. Costinean, B. D. Aguda, S. Volinia, M. Ferracin, J. Palatini, V. Balatti, et al.
Karyotype-specific microRNA signature in chronic lymphocytic leukemia
Blood,
October 29, 2009;
114(18):
3872 - 3879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delgado, D. W. Milligan, and P. Dreger
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
Blood,
September 24, 2009;
114(13):
2581 - 2588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. U. Knauf, T. Lissichkov, A. Aldaoud, A. Liberati, J. Loscertales, R. Herbrecht, G. Juliusson, G. Postner, L. Gercheva, S. Goranov, et al.
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
September 10, 2009;
27(26):
4378 - 4384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Abrisqueta, A. Pereira, C. Rozman, M. Aymerich, E. Gine, C. Moreno, A. Muntanola, M. Rozman, N. Villamor, K. Hodgson, et al.
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
Blood,
September 3, 2009;
114(10):
2044 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al.
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
J. Clin. Oncol.,
August 20, 2009;
27(24):
3994 - 4001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, N. E. Kay, K. G. Rabe, T. G. Call, C. S. Zent, K. Maddocks, G. Jenkins, D. F. Jelinek, W. G. Morice, J. Boysen, et al.
Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
August 20, 2009;
27(24):
3959 - 3963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, T. G. Call, C. S. Zent, B. LaPlant, D. A. Bowen, M. Roos, C. R. Secreto, A. K. Ghosh, B. F. Kabat, M.-J. Lee, et al.
Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
August 10, 2009;
27(23):
3808 - 3814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gill, D. Carney, D. Ritchie, M. Wolf, D. Westerman, H. M. Prince, H. Januszewicz, and J. F. Seymour
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy
Ann. Onc.,
July 22, 2009;
(2009)
mdp297v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dagklis, C. Fazi, C. Sala, V. Cantarelli, C. Scielzo, R. Massacane, D. Toniolo, F. Caligaris-Cappio, K. Stamatopoulos, and P. Ghia
The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring
Blood,
July 2, 2009;
114(1):
26 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Nieto, J. Almeida, A. Romero, C. Teodosio, A. Lopez, A. F. Henriques, M. L. Sanchez, M. Jara-Acevedo, A. Rasillo, M. Gonzalez, et al.
Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach
Blood,
July 2, 2009;
114(1):
33 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rossi, V. Spina, M. Cerri, S. Rasi, C. Deambrogi, L. De Paoli, L. Laurenti, R. Maffei, F. Forconi, F. Bertoni, et al.
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
Clin. Cancer Res.,
July 1, 2009;
15(13):
4415 - 4422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hanson, P. J. Kurtin, and A. Dogan
The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?
Blood,
June 18, 2009;
113(25):
6495 - 6496.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mulligan, M. E. Thomas, and S. P. Mulligan
Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL)
Blood,
June 18, 2009;
113(25):
6496 - 6497.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S Grove, G. A Follows, and W. N Erber
Incidental finding of lymphocytosis in an asymptomatic patient
BMJ,
June 10, 2009;
338(jun10_1):
b2119 - b2119.
[Full Text]
|
|
|
|
|
|
|
B. Eichhorst, M. Hallek, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Chronic lymphocytic leukemia: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv102 - iv104.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. E. Marti
The changing definition of CLL
Blood,
April 30, 2009;
113(18):
4130 - 4131.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, N. E. Kay, G. Jenkins, T. G. Call, C. S. Zent, D. F. Jelinek, W. G. Morice, J. Boysen, L. Zakko, S. Schwager, et al.
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome
Blood,
April 30, 2009;
113(18):
4188 - 4196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Angelo and R. Kurzrock
Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
February 15, 2009;
15(4):
1123 - 1125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al.
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
February 1, 2009;
27(4):
498 - 503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, et al.
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Clin. Cancer Res.,
February 1, 2009;
15(3):
995 - 1004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Pitini, C. Arrigo, and G. Altavilla
Dasatinib induces a response in chronic lymphocytic leukemia
Blood,
January 8, 2009;
113(2):
498 - 498.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kipps
Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
385 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mulligan, M. E. Thomas, and S. P. Mulligan
Monoclonal B-Lymphocytosis: Analysis of the Incidence, Demographics, Nature and Subclassification in 414 Patients
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
3129 - 3129.
[Abstract]
|
|
|
|
|
|
|
C. S. Mulligan, M. E. Thomas, S. P. Mulligan, A. C. Rawstron, and P. Hillmen
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
November 6, 2008;
359(19):
2065 - 2066.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schetelig, A. van Biezen, R. Brand, D. Caballero, R. Martino, M. Itala, J. A. Garcia-Marco, L. Volin, N. Schmitz, R. Schwerdtfeger, et al.
Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis
J. Clin. Oncol.,
November 1, 2008;
26(31):
5094 - 5100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Gunn, M. S. Mohammed, M. E. Gorre, P. D. Cotter, J. Kim, D. W. Bahler, S. N. Preobrazhensky, R. A. Higgins, A. R. Bolla, S. H. Ismail, et al.
Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia
J. Mol. Diagn.,
September 1, 2008;
10(5):
442 - 451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Blood,
August 15, 2008;
112(4):
975 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, F. L. Bennett, S. J.M. O'Connor, M. Kwok, J. A.L. Fenton, M. Plummer, R. de Tute, R. G. Owen, S. J. Richards, A. S. Jack, et al.
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
August 7, 2008;
359(6):
575 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Herbst, I. Monsef, N. Skoetz, and A. Engert
Eighth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Chronic Lymphatic Leukemia
J Natl Cancer Inst,
August 6, 2008;
100(15):
E1 - E1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
New Guidelines for Chronic Lymphocytic Leukemia
Journal Watch Oncology and Hematology,
July 29, 2008;
2008(729):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al.
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL
Blood,
July 15, 2008;
112(2):
394 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
